🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients

RecruitingPhase 4Ages 18 Years - anyAllPharmazz, Inc.
NCT05956418 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a prospective, multi-centric, open-labeled, phase-IV clinical study to evaluate the safety and efficacy of centhaquine citrate (LYFAQUIN™), a first-in-class drug for treating hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. Centhaquine has been found to be an effective resuscitative agent in rat, rabbit, and swine models of hemorrhagic shock. It has demonstrated the ability to decrease blood lactate levels, increase mean arterial pressure, enhance cardiac output, and reduce mortality rates. The increase in cardiac output during resuscitation is primarily attributed to an augmentation in stroke volume. Centhaquine exerts its effects by acting on the venous α2B-adrenergic receptors, which enhances venous return to the heart. Additionally, it produces arterial dilation by targeting central α2A-adrenergic receptors, thereby reducing sympathetic ac

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria • Adult hypovolemic shock patients aged 18 years or older admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Blood Lactate level indicative of hypovolemic shock (\>2.0 mmol/L). Exclusion Criteria * Development of any other terminal illness not associated with hypovolemic shock during the study duration. * Patient with altered consciousness not due to hypovolemic shock and comatose patient. • Known pregnancy. * Cardiopulmonary resuscitation (CPR) before enrollment. * Presence of a do not resuscitate order. * Patient is participating in another interventional study. * Patients with systemic diseases which were already present before having trauma, such as sepsis, cancer, chronic renal failure, liver failure, decompensated heart failure, or AIDS.
💊

What it tests

  • Centhaquine
📍

Where

17 sites
ACSR Government Medical College and Hospital
Nellore, India
All India Institute of Medical Sciences (AIIMS)
Raipur, India
Aman Hospital
Vadodara, India
New Era Hospital
Nagpur, India
Seven Star Hospital
Nagpur, India
Meditrina Hospital
Nagpur, India
Sri Guru Ram Das University of Health Sciences (SGRDH)
Amritsar, India
Dayanand Medical College & Hospital (DMCH)
Ludhiana, India

…and 9 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy